Elanco Animal Health IncELANEarnings & Financial Report

NYSE · pharmaceutical industry

Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.

NextMar 19, 2026

Revenue

$1.1B

Gross Profit

$607.0M

Operating Profit

$-50.0M

Net Profit

$-34.0M

Gross Margin

53.4%

Operating Margin

-4.4%

Net Margin

-3.0%

YoY Growth

10.4%

EPS

$-0.07

Financial Flow

Elanco Animal Health Inc Q3 2025 Financial Summary

Elanco Animal Health Inc reported revenue of $1.1B for Q3 2025, with a net profit of $-34.0M (-3.0% margin). Cost of goods sold was $530.0M, operating expenses totaled $657.0M.

Key Financial Metrics

Total Revenue	$1.1B
Net Profit	$-34.0M
Gross Margin	53.4%
Operating Margin	-4.4%
Report Period	Q3 2025

Elanco Animal Health Inc Annual Revenue by Year

Elanco Animal Health Inc annual revenue history includes year-by-year totals (for example, 2024 revenue was $4.4B).

Year	Annual Revenue
2024	$4.4B
2023	$4.4B
2022	$4.4B

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$1.03B	$1.21B	$1.18B	$1.03B	$1.02B	$1.19B	$1.24B	$1.14B
YoY Growth	5.5%	-4.1%	12.0%	-3.6%	-1.4%	-1.0%	4.8%	10.4%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$14.36B	$14.02B	$13.76B	$13.28B	$12.61B	$12.94B	$13.74B	$13.55B
Liabilities	$8.14B	$7.96B	$7.82B	$6.76B	$6.52B	$6.59B	$6.97B	$6.80B
Equity	$6.22B	$6.06B	$5.94B	$6.52B	$6.10B	$6.35B	$6.78B	$6.75B